Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 06, 2016 8:51 AM ET


Company Overview of Protea Biosciences Group, Inc

Company Overview

Protea Biosciences Group, Inc., molecular information company, develops and commercializes proprietary life science technologies, products, and services to identify the molecules that are produced by living cells and various life forms. The company provides molecular information services for the identification of small and large molecules; and tissue analytics services to create tissue-based molecular profiles. It also offers laser ablation electrospray ionization, a bioanalytical instrument platform that enables the identification of proteins, lipids, and metabolites in tissue, cells, and biofluids, such as serum and urine with minimal or without any sample preparation prior to analysis. It...

955 Hartman Run Road

Morgantown, WV 26507

United States

Founded in 2001

39 Employees





Key Executives for Protea Biosciences Group, Inc

Chairman, Chief Executive Officer and President
Age: 67
Total Annual Compensation: $240.0K
Chief Financial Officer
Age: 61
Total Annual Compensation: $145.6K
Chief Operating Officer and Vice President of Operations
Age: 46
Total Annual Compensation: $210.0K
Chief Science Officer and Vice President of Research & Development
Age: 40
Total Annual Compensation: $153.9K
Compensation as of Fiscal Year 2014.

Protea Biosciences Group, Inc Key Developments

Protea Biosciences Group Announces Memorandum of Understanding with Agilent Technologies

Protea Biosciences Group Inc. announced that it is collaborating with Agilent Technologies Inc. to address customer challenges within existing Biopharma bioanalytical workflows in order to meet the emerging needs of the growing biopharmaceutical industry. Under Terms of the Agreement, a Memorandum of Understanding (MOU), Protea, using Agilent instrumentation combined with its technology, will develop workflows that focus on developing new methods for the field of metabolomics.

Protea Biosciences Group, Inc Proposes Amendments to Certificate of Incorporation

Protea Biosciences Group Inc. proposed amendments to its certificate of incorporation, as amended (charter amendment), to effect a reverse stock split of common stock, $0.0001 par value per share (common stock), within a range of no less than 1:15 and no more than 1:25, with such ratio to be determined by the Board of Directors, in its sole discretion (reverse split), and with such Reverse Split to be effective at such time and date within one year after the date such action is approved by the stockholders, if at all, as determined by the Board of Directors in its sole discretion.

Protea Biosciences Group, Inc. Announces New Silicon Chip Technology

Protea Biosciences Group Inc. announced new, silicon chip technology that enables the rapid identification and quantitation of small molecules in biofluids. The announcement was made at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. Known as REDIchip ("Resonance-Enhanced Desorption Ionization"), the product employs a patented, "nanopost array" (NAPA) nanotechnology invented in the laboratory of Prof. Akos Vertes, PhD., Department of Chemistry, The George Washington University, and exclusively licensed to Protea. REDIchip technology was developed by Protea in conjunction with a $14 million DARPA cooperative research agreement led by The George Washington University and including GE Global Research and SRI International. The project goal is to develop new tools to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days from exposure. Uncovering the mechanism of action of such agents in 30 days compared to the years currently required will enhance and support the development of effective threat mitigations and countermeasures. REDIchip is formatted as a disposable, single use, 96 spot, target plate, suitable for simple and complex biological mixtures, and compatible with most standard MALDI-MS instrument systems.

Similar Private Companies By Industry

Company Name Region
Applied Veterinary Systems United States
ADS Biotechnology, Ltd. United States
Smart Biosciences, Inc. United States
Rodin Therapeutics Inc. United States
Triton Algae Innovations Ltd. United States

Recent Private Companies Transactions

Private Placement
August 27, 2015
Private Placement
May 22, 2015
April 6, 2015
vivoPharm Pty.Ltd.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Protea Biosciences Group, Inc, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at